Goldman Sachs resumed coverage of Altimmune (ALT) with a Sell rating and $1 price target representing 79% downside. The company’s data to-date has not demonstrated a meaningfully differentiated profile for pemvidutide in either obesity or metabolic dysfunction associated steatohepatitis, the analyst tells investors in a research note. The firm sees challenges for Altimmune to execute the full clinical development program required to bring pemvidutide to market.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Sell Rating for Altimmune Inc. Due to Financial Struggles and Competitive Challenges in Drug Development
- Altimmune’s RESTORE TRIAL: A Promising Step in ALD Treatment
- Altimmune enrolls first patient in Restore Phase 2 trial
- Altimmune’s Pemvidutide: A Promising Candidate for MASH Market with Strong Phase 3 Potential
- Optimistic Outlook for Altimmune’s Pemvidutide Despite Phase 2b Setback